Skin Cancer – Research Article

Ye Q.a· Wu Q.b· Jia M.a· Li F.-Z.a· Fang S.a

Author affiliations

aThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China
bQijiang Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: March 30, 2022
Accepted: July 16, 2022
Published online: September 09, 2022

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 4

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Although various benign and malignant tumors can arise in nevus sebaceus (NS), the demographic and clinicopathological features of the secondary tumors vary among different published reports. The aim of this study was to obtain a better understanding of the features of tumors secondary to NS. Methods: A multicenter study was performed by reviewing patients diagnosed with NS from the Dermatology Department of the First Affiliated Hospital of Chongqing Medical University and Qijiang Hospital of the First Affiliated Hospital of Chongqing Medical University from 2010 to 2022. A literature review of case series of secondary tumors arising in NS was also conducted. Results: We retrospectively analyzed the literature on tumors secondary to NS published since 2000, with a total of 443 cases, and carefully studied cases of tumors arising in NS from multiple centers since 2010, with a total of 54 cases. There were 497 cases in this study; 90.3% were benign tumors (n = 449), and the rest were malignant tumors (9.7%, n = 48). Syringocystadenoma papilliferum was the most common benign tumor, followed by trichoblastoma and trichilemmoma. Basal cell carcinoma was the most common secondary malignant tumor to NS, followed by squamous cell carcinoma. Two of these cases developed metastasis. Secondary malignancies developed at an earlier age in Caucasians than in Hispanics and Asians. Conclusion: The present study is the largest analysis of tumors secondary to NS. Racial differences were seen in secondary tumors to NS and may contribute to healthcare disparities between races.

© 2022 S. Karger AG, Basel

References Baykal C, Buyukbabani N, Yazganoglu KD, Saglik E. Mit Naevus sebaceus assoziierte Tumoren [Tumors associated with nevus sebaceous]. J Dtsch Dermatol Ges. 2006;4(1):28–31. Rosen H, Schmidt B, Lam HP, Meara JG, Labow BI. Management of nevus sebaceous and the risk of Basal cell carcinoma: an 18-year review. Pediatr Dermatol. 2009;26(6):676–81. Muñoz-Pérez MA, García-Hernandez MJ, Ríos JJ, Camacho F. Sebaceus naevi: a clinicopathologic study. J Eur Acad Dermatol Venereol. 2002;16(4):319–24. Jaqueti G, Requena L, Sánchez Yus E. Trichoblastoma is the most common neoplasm developed in nevus sebaceus of Jadassohn: a clinicopathologic study of a series of 155 cases. Am J Dermatopathol. 2000;22(2):108–18. Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceus: a study of 596 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):263–8. Idriss MH, Elston DM. Secondary neoplasms associated with nevus sebaceus of Jadassohn: a study of 707 cases. J Am Acad Dermatol. 2014;70(2):332–7. Kamyab-Hesari K, Seirafi H, Jahan S, Aghazadeh N, Hejazi P, Azizpour A, et al. Nevus sebaceus: a clinicopathological study of 168 cases and review of the literature. Int J Dermatol. 2016;55(2):193–200. Hsu MC, Liau JY, Hong JL, Cheng Y, Liao YH, Chen JS, et al. Secondary neoplasms arising from nevus sebaceus: a retrospective study of 450 cases in Taiwan. J Dermatol. 2016;43(2):175–80. Lukowiak TM, Aizman L, Perz A, Miller CJ, Sobanko JF, Shin TM, et al. Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States. JAMA Dermatol. 2020;156(11):1192–8. Santibanez-Gallerani A, Marshall D, Duarte AM, Melnick SJ, Thaller S. Should nevus sebaceus of Jadassohn in children be excised? A study of 757 cases, and literature review. J Craniofac Surg. 2003;14(5):658–60. Elewa RM, Abdallah MA, Zouboulis CC. Age-associated skin changes in innate immunity markers reflect a complex interaction between aging mechanisms in the sebaceous gland. J Dermatol. 2015;42(5):467–76. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer. 2004;4(1):23–35. Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al. Basal cell carcinoma: a comprehensive review. Int J Mol Sci. 2020 Aug 4;21(15):5572. Aslam A, Salam A, Griffiths CEM, McGrath JA. Naevus sebaceus: a mosaic RASopathy. Clin Exp Dermatol. 2014;39(1):1–6. Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012;44(7):783–7. Shen AS, Peterhof E, Kind P, Rütten A, Zelger B, Landthaler M, et al. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Hum Pathol. 2015;46(2):272–6. Strange RC, El-Genidy N, Ramachandran S, Lovatt TJ, Fryer AA, Smith AG, et al. Susceptibility to basal cell carcinoma: associations with PTCH polymorphisms. Ann Hum Genet. 2004;68(Pt 6):536–45. Xin H, Matt D, Qin JZ, Burg G, Böni R. The sebaceous nevus: a nevus with deletions of the PTCH gene. Cancer Res. 1999;59(8):1834–6. Kneitz H, Goebeler M, Rütten A. Nevus sebaceous of the scalp with stepwise progression into invasive syringocystadenocarcinoma papilliferum. Am J Dermatopathol. 2021 Dec 1;43(12):965–9. Manonukul J, Omeapinyan P, Vongjirad A. Mucoepidermoid (adenosquamous) carcinoma, trichoblastoma, trichilemmoma, sebaceous adenoma, tumor of follicular infundibulum and syringocystadenoma papilliferum arising within 2 persistent lesions of nevus sebaceous: report of a case. Am J Dermatopathol. 2009;31(7):658–63. Arshad AR, Azman WS, Kreetharan A. Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck. 2008;30(4):544–8. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55(5):741–60; quiz 761–4. Al Mushcab N, Husain R, Al Subaiei M, Al Qarni A, Abbas A, Al Duhileb M. Trichoblastoma mimicking basal cell carcinoma and the approach to its management: case report. Int J Surg Case Rep. 2021;86:106318. Article / Publication Details

First-Page Preview

Received: March 30, 2022
Accepted: July 16, 2022
Published online: September 09, 2022

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 4

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.